Reviews Fentanyl Buccal Tablet


No reviews yet.

Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009





Other reviews about Fentanyl Buccal Tablet on wordpress

painkiller implicated in headache patient deaths
  by Diana Lee
A painkiller called Fentora is being blamed for four deaths, two of them headache patients. The headline of this article is slightly misleading because it seems to imply […]


Important Safety Information for Fentora (Fentanyl buccal tablet)
  by heremias
On September 10th 2007, Cephalon, Inc., the manufacturer of Fentora (Fentanyl buccal tablet) issued both a Dear Doctor and a Dear Healthcare Professional letter in response to the […]


FDA Warns About Misuse Of Fentora Cancer Pain Drug
  by DreamHealer
The US Food and Drug Administration (FDA) has issued a warning, alerting health professionals and patients about the potential misuse and side effects of Fentora (fentanyl buccal), a […]


Recycling unused prescription drugs
  by lniemi
Question: We have had some recent deaths in our family and have a quantity of unused prescription medication. Some of it is in sealed individual doses. It just […]


Blog Action Day: The Environment
  by dustinbrookshire
Last night while catching up on blogs, I discovered today is Blog Action Day. Today, thousands of bloggers are writing on the topic of the environment. I wanted […]


Written and video instruction home disposal of prescription drugs
  by naturalgal
http://www.whitehousedrugpolicy.gov/drugfact/disposal.mov If you don't have a disposal site near your please watch this video on how to disposal of prescription medicine Remember, never quit psychotropic medication cold turkey. You need […]


What is the proper way to dispose of expired or unwanted medications in your home?
  by Lawyer Sanders
How do you properly dispose of old or unwanted medicines found in your medicine cabinets?  Should you flush them down the toilet?  Should you throw them in the […]


The Science
  by cmoxley
R.A.S.E.R. Technology: Was developed to take advantage of the benefits that buccal mucosa delivery may provide. Rapid-Acting, Side-Effect-Reducing. Buccal Mucosa Delivery: Unlike conventional dietary supplements, which are absorbed exclusively […]


Safe Disposal Of Prescription Drugs
  by handicapper
Prescription drugs are now the second most commonly abused category of drugs, behind marijuana and ahead of cocaine, heroin, methamphetamine, and other drugs. Some of the abuse occurs when […]


Pharmacist Discovers Effective Hoodia Weight Loss Product
  by Keith Abell
Hi I am Keith Abell, I am a pharmacist and a Silver Executive with Essante Worldwide. I am so excited to be with this company and even more excited […]



Other reviews about Fentanyl Buccal Tablet on web:

Fentanyl buccal tablet To return to the main entry click here . What is Fentanyl buccal tablet? FENTANYL (Fentora) relieves pain flares or Fentanyl buccal tablet: Information from Answers.com


Learn about the prescription medication Fentora (Fentanyl Buccal Tablet), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Fentora (Fentanyl Buccal Tablet) Drug Information: Uses, Side ...


Read about Fentora (fentanyl-buccal) an opiate derivative drug prescribed for breakthrough cancer pain. Side effects, dosage, warnings, and precautions are discussed in the topic ... Fentanyl buccal (Fentora) Drug Information on MedicineNet.com


Fentanyl Citrate Buccal tablet To return to the main entry click here . What is this medicine? FENTANYL (FEN ta nil) is a pain reliever Fentanyl Citrate Buccal tablet: Information from Answers.com


1. Drugs Today (Barc). 2008 Jan;44(1):41-54. Fentanyl buccal tablet. Messina J, Darwish M, Fine PG. Cephalon, Inc., Frazer, Pennsylvania 19355, USA. jmessina@cephalon.com Fentanyl buccal tablet.


The medication in fentanyl lozenges is absorbed differently by the body than the medication in fentanyl buccal tablets, so one product cannot be substituted for the other. Fentanyl Buccal (Transmucosal): MedlinePlus Drug Information


Fentanyl Effervescent Buccal Tablets in the Treatment of BTP: Learn about the features of fentanyl effervescent buccal tablets (FEBT) which are currently in development for chronic ... Fentanyl Effervescent Buccal Tablets in Chronic Pain: Fentanyl ...


Drug Evaluation 10.1517/13543784.15.11.1469 © 2006 Informa UK Ltd ISSN 1354-3784 1469 Fentanyl buccal tablets Lynn R Webster Lifetree Clinical Research and Pain Clinic, Salt Lake City ... Fentanyl buccal tablets


Fentanyl Tablet - Buccal glossary includes a list of Fentanyl Tablet - Buccal related medical definitions and related links on MedicineNet.com Fentanyl Tablet - Buccal Glossary of Terms with Definitions on ...


Efficacy and Safety of Fentanyl Buccal Tablets Compared With Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain Efficacy and Safety of Fentanyl Buccal Tablets Compared With ...





Featured Reviews

Reviews Cyclosporine

Sandimmune Drug Description Sandimmune® (cyclosporine, USP) Soft Gelatin Capsules Sandimmune® (cyclosporine, USP) Oral Solution Sandimmune® (cyclosporine, USP) Injection WARNING Only physicians experienced in immunosuppressi...
Read More  |  Review This
Reviews Betamethasone

Celestone Syrup Drug Description Celestone® (betamethasone) Syrup, USP DRUG DESCRIPTION What are the possible side effects of betamethasone (Celestone)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Clarithromycin

Biaxin, Biaxin XL Drug Description BIAXIN® Filmtab® (clarithromycin) Tablets, USP BIAXIN® XL Filmtab® (clarithromycin) Extended-Release Tablets BIAXIN® Granules (clarithromycin) for Oral Suspension, USP To reduce...
Read More  |  Review This
Reviews Cyanokit

Cyanokit Drug Description Cyanokit® (hydroxocobalamin) for Injection 5 g for Intravenous Infusion DRUG DESCRIPTION What are the possible side effects of hydroxocobalamin (Cyanokit)? Get emergency medical help if you have any...
Read More  |  Review This
Reviews Ropivacaine Hcl

Naropin Drug Description NAROPIN® (ropivacaine HCl) Injection DRUG DESCRIPTION What are the possible side effects of ropivacaine (Naropin, Naropin Polyamp, Naropin SDV)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....